ScreenerHero

KMDA Kamada Ltd.

NAS · US · Healthcare · Drug Manufacturers - Specialty & Generic · kamada.com
7.890USD-2.71%Mkt Cap: 455.33M $P/E: 20.23

Kamada Ltd. manufactures and sells plasma-derived protein therapeutics. Its products include KAMRAB/KEDRAB indicated as prophylaxis of rabies; CYTOGAM for prophylaxis of Cytomegalovirus disease in kidney, lung, liver, pa…

Industry Peers

Drug Manufacturers - Specialty & Generic
Screen all
MRK
Merck KGaA
$66.23BUSDP/E 25.7
TAK
Takeda Pharmaceutical Company Limited
$58.68BUSD
TEVA
Teva Pharmaceutical Industries Limited
$45.70BUSDP/E 65.3
GALD
Galderma Group AG
$43.27BUSDP/E 56.1
HLN
Haleon plc
$39.67BUSDP/E 18.4
SDZ
Sandoz Group AG
$34.93BUSDP/E 60.5
HLN
Haleon plc
$32.73BUSDP/E 19.0
ZOE
Zoetis Inc.
$28.56BUSDP/E 12.2
ZTS
Zoetis Inc.
$29.57BUSDP/E 11.8
UTHR
United Therapeutics Corporation
$23.38BUSDP/E 19.5
VTRS
Viatris Inc.
$20.09BUSD
SOBI
Swedish Orphan Biovitrum AB (publ)
$14.43BUSDP/E 112.9
NBIX
Neurocrine Biosciences, Inc.
$14.58BUSDP/E 21.0
IPN
Ipsen S.A.
$12.99BUSDP/E 23.5
ELAN
Elanco Animal Health Incorporated
$11.17BUSD
RDY
Dr. Reddy's Laboratories Limited
$10.22BUSDP/E 27.9
KRK
Krka, d. d.
$8.66BUSDP/E 19.3
ALKS
Alkermes plc
$6.95BUSDP/E 109.1
HIMS
Hims & Hers Health, Inc.
$6.89BUSD
AMRX
Amneal Pharmaceuticals, Inc.
$6.84BUSDP/E 40.1

Key Statistics

Company
Market Cap455.33M USD
Enterprise Value411.14M USD
Revenue (TTM)191.85M USD
Gross Profit76.41M USD
Net Income (TTM)20.20M USD
Revenue/Share3.28 USD
Last Price7.890 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees462
CountryUS
SectorHealthcare
IndustryDrug Manufacturers - Specialty & Generic
ISIN—
Valuation
P/E (Trailing)20.23
P/E (Forward)14.06
PEG0.60
EV/EBITDA9.91
EV/Revenue2.14
P/S2.44
P/B1.74
EPS (TTM)0.37
EPS (Forward)0.58
52W Range
6.50049% of range9.350
52W High9.350 USD
52W Low6.500 USD
Profitability
Gross Margin42.34%
Oper. Margin17.32%
EBITDA Margin21.63%
Profit Margin11.19%
ROE7.51%
ROA5.33%
Growth
Revenue Growth22.70%
Earnings Growth23.10%
Cash Flow & Leverage
Operating CF25.49M USD
CapEx (TTM)9.85M USD
FCF Margin8.08%
FCF Yield3.41%
Net Debt-58.33M USD
Net Debt/EBITDA-1.41
Balance Sheet
Debt/Equity0.04
Current Ratio4.06
Quick Ratio2.29
Book Value/Sh4.66 USD
Cash/Share1.21 USD
Dividends
Fwd Div Rate0.17 USD
Trail. Div Rate0.25 USD
Div. Yield2.13%
5Y Avg Yield—
Payout Ratio65.79%
Ex-Div DateAug 27, 2026
Pay DateSep 17, 2026
Analyst Consensus
Rating1.0 (Strong Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)13.50 USD
Upside (mean)+71.1%
Target Range11.00 USD – 15.00 USD
11.00+71.1% to mean15.00
# Analysts4
Ownership
Shares Out.57.71M
Float33.18M
Insiders6.99%
Institutions49.17%
Short Interest
Short Ratio0.9d
Short % Float0.51%
Short % Out.0.28%
Shares Short160.82K
Short (prev mo.)149.55K
Technical
SMA 507.995 (-1.3%)
SMA 2007.980 (-1.1%)
Beta0.13
S&P 52W Chg15.78%
Avg Vol (30d)149.15K
Avg Vol (10d)102.81K
Technical Indicators
RSI (14)42.3
MACD0.0352
MACD Signal0.1520
MACD Hist.-0.1168
BB Upper9.075 USD
BB Middle8.394 USD
BB Lower7.712 USD
BB Width16.23%
ATR (14)0.2703 USD
Vol Ratio (20d)0.53x